• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
76,264.33 736.38
( 0.97%)
Global Indices
Nasdaq
51,233.54 363.79
(0.72%)
Dow Jones
7,453.14 37.84
(0.51%)
Hang Seng
69,318.21 3,298.17
(5.00%)
Nikkei 225
10,435.69 -36.03
(-0.34%)
Forex
USD-INR
95.49 0.16
(0.17%)
EUR-INR
110.25 0.17
(0.15%)
GBP-INR
127.74 0.15
(0.12%)
JPY-INR
0.60 0.00
(0.21%)

EQUITY - MARKET SCREENER

IRB InvIT Fund
Industry :  Construction
BSE Code
ISIN Demat
Book Value()
540526
INE183W23014
105.4574955
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
IRBINVIT
6.78
4779.7
EPS(TTM)
Face Value()
Div & Yield %
8.91
102
9.47
 

incap ltd
Alembic slides as Q4 PAT tanks 60% YoY to Rs 10 cr
May 20,2026

Revenue from operations margianlly shed 0.38% year on year (YoY) to Rs 60.04 crore in the quarter ended 31 March 2026.

Profit before tax (PBT) stood at Rs 18.44 crore in Q4 FY26, down 31.50% from Rs 26.92 crore recorded in the same quarter last year.

Total expenses jumped 20.42% YoY to Rs 43.74 crore in Q4 FY26. The cost of materials consumed stood at Rs 4.04 crore (up 110.41% YoY), while employee benefit expenses rose 80.61% YoY to Rs 11.74 crore during the period under review.

The company recommended a dividend of Rs 2.40 per equity share of face value Rs 2 each (120%) for FY26.

Alembic is dealing in Active Pharmaceutical Ingredient (API) Business and Real Estate Business.